Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 1
2013 1
2014 2
2015 2
2016 6
2017 5
2018 5
2019 6
2020 4
2021 5
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. Among authors: crusoe e. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, Pika T, Tovar N, Schutz N, Ciofini S, Peña C, Rocchi S, Rassner M, Avivi I, Waszczuk-Gajda A, Chhabra S, Usnarska-Zubkiewicz L, González-Calle V, Mateos MV, Bocchia M, Bigi F, Füllgraf H, Bhasin-Chhabra B, Gentile M, Davila J, Vesole DH, Cavo M, Thapa B, Crusoe E, Einsele H, Legiec W, Charliński G, Jurczyszyn A. Gozzetti A, et al. Among authors: crusoe e. Am J Hematol. 2022 Jul;97(7):877-884. doi: 10.1002/ajh.26566. Epub 2022 Apr 20. Am J Hematol. 2022. PMID: 35389534 Free PMC article.
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Avivi I, Vesole DH, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, Baumert B, Osękowska B, Kopińska A, Gentile M, Puertas-Martinez B, Robak P, Crusoe E, Rodriguez-Lobato LG, Gajewska M, Varga G, Delforge M, Cohen Y, Gozzetti A, Pena C, Shustik C, Mikala G, Zalac K, Alexander HD, Barth P, Weisel K, Martínez-López J, Waszczuk-Gajda A, Krzystański M, Jurczyszyn A. Avivi I, et al. Among authors: crusoe e. Cancers (Basel). 2023 Sep 1;15(17):4359. doi: 10.3390/cancers15174359. Cancers (Basel). 2023. PMID: 37686635 Free PMC article.
New proteasome inhibitors in the treatment of multiple myeloma.
Hungria VTM, Crusoé EQ, Bittencourt RI, Maiolino A, Magalhães RJP, Sobrinho JDN, Pinto JV, Fortes RC, Moreira ES, Tanaka PY. Hungria VTM, et al. Among authors: crusoe eq. Hematol Transfus Cell Ther. 2019 Jan-Mar;41(1):76-83. doi: 10.1016/j.htct.2018.07.003. Epub 2018 Oct 15. Hematol Transfus Cell Ther. 2019. PMID: 30793108 Free PMC article. Review.
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I.
Maiolino A, Crusoé EQ, Martinez GA, Braga WMT, de Farias DLC, Bittencourt RI, Neto JVP, Ribeiro GN, Bernardo WM, Tristão L, Magalhaes RJP, Hungria VTM. Maiolino A, et al. Among authors: crusoe eq. Hematol Transfus Cell Ther. 2022 Jul-Sep;44(3):410-418. doi: 10.1016/j.htct.2022.06.003. Epub 2022 Jul 20. Hematol Transfus Cell Ther. 2022. PMID: 35970751 Free PMC article. No abstract available.
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients.
Maiolino A, Costa LJ, Pasquini M, Crusoe EQ, Vigorito AC, Salvino MA, Seguro FS, Filho JS, Hungria VTM. Maiolino A, et al. Among authors: crusoe eq. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S30-S34. doi: 10.1016/j.htct.2021.09.004. Hematol Transfus Cell Ther. 2021. PMID: 34794794 Free PMC article.
Equity program: strategies on clinical studies as an aggregating potential.
Crusoe EQ, Hallack Neto AE, Nantes DF, Ribeiro EFO, Pinto FMC, Bortolini JAP, Maciel JFR, Marques Junior JFC, Corrêa LC, Capra MEZ, Carvalho MDPSS, de Melo NS, Quintas RVO, Carneiro TX, Laforga VP, Cunha RLG. Crusoe EQ, et al. Hematol Transfus Cell Ther. 2023 Oct-Dec;45(4):417-418. doi: 10.1016/j.htct.2023.07.001. Epub 2023 Jul 13. Hematol Transfus Cell Ther. 2023. PMID: 37500357 Free PMC article. No abstract available.
Observational study of multiple myeloma in Latin America.
Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, Peters L, Colleoni G, Oliveira LC, Crusoé E, Coelho ÉO, Pasquini R, Magalhães SM, Nunes R, Neto JV, Faria RM, Souza M, Hamerschlak N, Flantl D, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Argüelles G, Durie BG; International Myeloma Working Group Latin America. Hungria VT, et al. Among authors: crusoe e. Ann Hematol. 2017 Jan;96(1):65-72. doi: 10.1007/s00277-016-2866-9. Epub 2016 Nov 5. Ann Hematol. 2017. PMID: 27815724
36 results